AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$8.82
+$0.14 (+1.56%) 4:00 PM ET
After hours$8.88
+$0.07 (+0.74%) 4:15 PM ET
Prev closePrevC$8.68
OpenOpen$8.70
Day highHigh$8.90
Day lowLow$8.68
VolumeVol2,714,645
Avg volAvgVol3,388,154
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$2.01B
P/E ratio
12.96
FY Revenue
$509.86M
EPS
0.68
Gross Margin
61.27%
Sector
Healthcare
AI report sections
MIXED
ADMA
ADMA Biologics, Inc.
ADMA combines high margins, positive earnings, and low leverage with sharp recent share price declines and heavy downside momentum. Valuation appears moderate on earnings and EBITDA metrics but is offset by very low free cash flow yield and a notable drop in net income growth. Elevated short interest and a newly disclosed securities investigation add incremental sentiment and headline risk around an otherwise profitable operating profile.
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud for the period between August 9, 2024 and March 25, 2026. The complaint claims the company made false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. Investors who suffered losses have until August 10, 2026 to request lead plaintiff status.
ADMAclass action lawsuitsecurities fraudADMA Biologicschannel stuffingrelated party transactioninternal controlsinvestor harm
Sentiment note
The company is the subject of a securities fraud class action lawsuit alleging undisclosed related party transactions, channel stuffing to inflate revenue, inadequate internal controls, and materially false statements about business operations and prospects.
NegativeGlobeNewswire Inc.• Rosen Law Firm
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.
ADMAsecurities class actionADMA Biologicslead plaintiff deadlinerelated party transactionchannel stuffinginternal controlsinvestor compensation
Sentiment note
The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations indicate serious corporate governance and accounting issues that resulted in investor losses.
NegativeGlobeNewswire Inc.• Rosen Law Firm
רוזן, חברת שפתחה בהליכים ראשונה, מעודדת את המשקיעים ב-ADMA BIOLOGICS, Inc לקבל ייעוץ משפטי לפני המועד האחרון החשוב בתביעה ייצוגית בניירות ערך שהוגשה לראשונה על ידי החברה – ADMA
Rosen Law Firm reminds investors in ADMA Biologics, Inc. (NASDAQ: ADMA) of the August 10, 2026 deadline to join a securities class action lawsuit. The firm alleges that ADMA made false statements regarding undisclosed related-party transactions, channel stuffing practices, inadequate internal controls, and misleading revenue representations during the period from August 9, 2024 to March 25, 2026.
The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related-party transactions, channel stuffing to inflate revenues, and inadequate internal controls. These allegations indicate serious corporate governance and financial reporting violations that caused investor losses.
NegativeGlobeNewswire Inc.• Rosen Law Firm
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.
ADMAsecurities class actionADMA Biologicsinvestor lawsuitlead plaintiff deadlinerelated party transactionchannel stuffinginternal controls
Sentiment note
The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations suggest serious corporate governance and financial reporting issues that resulted in investor losses.
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
A class action lawsuit has been filed against ADMA Biologics for alleged securities fraud. Culper Research published a report claiming the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth in 2025. The allegations led to a 29.1% stock price decline on March 25, 2026. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 can file a lead plaintiff motion by August 10, 2026.
The company is the subject of a securities fraud lawsuit alleging channel stuffing, undisclosed related party transactions, and false revenue reporting. These allegations resulted in a significant 29.1% stock price decline, indicating serious legal and financial risks for shareholders.
ADMA Biologics (NASDAQ:ADMA) Channel Stuffing Claims Trigger Securities Fraud Class Action – Investors Notified to Contact BFA Law about the Lawsuit
ADMA Biologics faces a securities fraud class action lawsuit after Culper Research alleged the company engaged in channel stuffing to artificially inflate 2025 revenue growth from -3% to reported +20%. The allegations triggered a 29% stock decline, with the largest single-day drop of 16.6% on March 24, 2026. Investors have until August 10, 2026, to request lead plaintiff status.
ADMAchannel stuffingsecurities fraudclass action lawsuitrevenue manipulationASCENIVrelated party transactionsstock decline
Sentiment note
Company faces securities fraud allegations for channel stuffing scheme that artificially inflated reported revenue growth. Stock declined 29% following investigative report revealing actual revenue decline of 3% versus reported 20% growth. Class action lawsuit filed with significant investor losses.
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud for the period between August 9, 2024 and March 25, 2026. The complaint claims the company made false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. Investors who suffered losses have until August 10, 2026 to request lead plaintiff status.
ADMAclass action lawsuitsecurities fraudADMA Biologicschannel stuffingrelated party transactioninternal controlsinvestor harm
Sentiment note
The company is the subject of a securities fraud class action lawsuit alleging undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations indicate serious corporate governance and financial reporting violations that harm investor confidence and shareholder value.
Bronstein, Gewirtz & Grossman LLC Urges First Solar, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against First Solar, Inc. alleging that company defendants made materially false and misleading statements regarding the company's ability to manage U.S. tariff policy impacts. The complaint claims defendants overstated capacity and understated negative effects from production facility underutilization in Malaysia and Vietnam, as well as U.S. relocation efforts, which would harm 2026 fiscal year performance. Investors who purchased First Solar securities between February 26, 2025 and February 24, 2026 are encouraged to join the case.
ADMA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
ADMA Biologics faces a securities class action lawsuit alleging the company made false statements regarding undisclosed related party transactions, channel stuffing schemes, and inadequate internal controls. A Culper Research report claimed ADMA's reported 20% growth was artificially inflated through extended payment terms, with actual revenue declining 3% in 2025. The stock fell over 16% following the report and an additional 13% after a Cantor Fitzgerald downgrade.
Company is facing securities fraud allegations involving channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock declined significantly (16% and 13%) following negative reports and analyst downgrades. The lawsuit alleges material misstatements about revenue growth.
NegativeGlobeNewswire Inc.• Law Offices Of Howard G. Smith
DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Law Offices of Howard G. Smith announced securities fraud class action lawsuits against four publicly-traded companies: BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. The complaints allege that defendants made false or misleading statements regarding their business operations, financial performance, and prospects. Investors have until August 7-10, 2026 to file lead plaintiff motions.
Defendants allegedly engaged in undisclosed related party transactions, channel stuffing, lacked adequate internal controls, and made misleading statements about business operations.
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud involving undisclosed related party transactions, channel stuffing, and inadequate internal controls during the period from August 9, 2024 to March 25, 2026. Investors who purchased ADMA securities during this period are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026.
ADMAclass action lawsuitsecurities fraudADMA Biologicschannel stuffingrelated party transactioninternal controlsinvestor harm
Sentiment note
The company is the subject of a securities fraud class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing practices, and inadequate internal controls, which directly harm investor interests and indicate serious corporate governance and accounting violations.
NegativeGlobeNewswire Inc.• Faruqi & Faruqi, Llp
ADMA CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
ADMA Biologics faces a federal securities class action lawsuit alleging the company made false statements about its financial performance through channel stuffing schemes and undisclosed related party transactions. An investigative report revealed ADMA artificially inflated 2025 revenue growth from -3% to +20% by inducing distributors to overstock products with rebates and extended payment terms. The stock declined 29% following the report's publication on March 24, 2026. Investors who purchased securities between August 9, 2024 and March 25, 2026 may be eligible to participate, with a deadline of August 10, 2026 to seek lead plaintiff status.
ADMAsecurities fraudchannel stuffingrelated party transactionclass action lawsuitinternal controlsrevenue manipulationlead plaintiff
Sentiment note
The company is accused of material securities fraud including channel stuffing, undisclosed related party transactions, and inadequate internal controls. The stock experienced a 29% decline following the investigative report, and the company faces significant legal liability and reputational damage from the class action lawsuit.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
